AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $244.45, with a market capitalization of 431.88B. The stock trades at a price-to-earnings (P/E) ratio of 122.32 and offers a dividend yield of 2.72%.
On 2026-07-14, AbbVie(ABBV) stock traded between a low of $243.31 and a high of $247.50. Shares are currently priced at $244.45, which is +0.5% above the low and -1.2% below the high.
AbbVie(ABBV) shares are trading with a volume of 878.27K, against a daily average of 7.07M.
During the past year, AbbVie(ABBV) stock moved between $184.63 at its lowest and $261.64 at its peak.
During the past year, AbbVie(ABBV) stock moved between $184.63 at its lowest and $261.64 at its peak.
ABBV News
Key Points Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally. Strong p...
UBS raised the firm’s price target on AbbVie (ABBV) to $260 from $230 and keeps a Neutral rating on the shares. TipRanks has entered a new arena in the investi...
Key Points AbbVie has a portfolio of attractive drugs, including branded products that are off-patent but still highly profitable. The company's acquisition o...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (ABBV) is back in focus after the European Commission approved Tepkinly plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, p...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.